Table 3. Clinicopathologic characteristics according to adjuvant chemotherapy regimens.
| Characteristic | AC (n = 1,419) No. (%) |
FAC (n = 875) No. (%) |
CMF (n = 1,190) No. (%) |
None (n = 549) No. (%) |
p-value |
|---|---|---|---|---|---|
| Age (yr) | < 0.001 | ||||
| ≤ 50 | 915 (64.5) | 587 (67.1) | 687 (57.7) | 247 (45.0) | |
| > 50 | 501 (35.3) | 288 (32.9) | 503 (42.3) | 300 (54.6) | |
| Unknown | 3 (0.2) | 2 (0.4) | |||
| T stage | < 0.001 | ||||
| T1 | 707 (49.8) | 379 (43.3) | 642 (53.9) | 435 (79.2) | |
| T2 | 712 (50.2) | 496 (56.7) | 548 (46.1) | 114 (20.8) | |
| Histologic grade | < 0.001 | ||||
| I | 44 (3.1) | 13 (1.5) | 84 (7.1) | 57 (10.4) | |
| II | 372 (26.2) | 102 (11.7) | 321 (27.0) | 169 (30.8) | |
| III | 883 (62.2) | 669 (76.5) | 573 (48.2) | 175 (31.9) | |
| Unknown | 120 (8.5) | 91 (10.4) | 212 (17.8) | 148 (27.0) | |
| LVI | < 0.001 | ||||
| No | 1,085 (76.5) | 434 (49.6) | 745 (62.6) | 377 (68.7) | |
| Yes | 172 (12.1) | 235 (26.9) | 141 (11.8) | 43 (7.8) | |
| Unknown | 162 (11.4) | 206 (23.5) | 304 (25.5) | 129 (23.5) | |
| Operation | < 0.001 | ||||
| Mastectomy | 544 (38.3) | 251 (28.7) | 608 (51.1) | 271 (49.4) | |
| BCS | 870 (61.3) | 616 (70.4) | 571 (48.0) | 275 (50.1) | |
| Unknown | 5 (0.4) | 8 (0.9) | 11 (0.9) | 3 (0.5) |
AC=anthracyclin and cyclophosphamide; FAC=5-fluorouracil, anthracyclin, and cyclophosphamide; CMF=cyclophosphamide, methotrexate, and 5-fluorouracil; LVI=lymphovascular invasion; BCS=breast-conserving surgery.